United States v. Girod
| Decision Date | 21 July 2016 |
| Docket Number | Criminal Action No. 5: 15-87-DCR |
| Parties | UNITED STATES OF AMERICA, Plaintiff, v. SAMUEL A. GIROD, Defendant. |
| Court | U.S. District Court — Eastern District of Kentucky |
This matter is pending for consideration of the United States' motions in limine, asking the Court to exclude: (i) Defendant Samuel Girod's proposed "expert" testimony at trial; and (ii) his evidence concerning a Private Membership Association as a defense at trial. [Record Nos. 67; 68] The defendant has not filed any responses in opposition to these motions, and the time to do so has expired. Thus, they are ripe for review. For the reasons outlined below, the Court will grant the motions in limine.
A more detailed factual summary of this matter appears in the Court's June 22, 2016 Memorandum Opinion and Order denying Girod's motion in limine. [Record No. 66, pp. 1-3] In essence, Girod is charged with twelve counts ranging from obstruction of justice to introducing into interstate commerce misbranded products in violation of 21 U.S.C. §§ 33l(a) and 333(a)(2). [Record No. 1, ¶¶ 17-44] The charges center around his manufacturing and distribution of certain salves at an establishment not registered with the Food and Drug Administration ("FDA") under 21 U.S.C. § 360(b)(l), (c)(l).
On June 24, 2016, the Court denied the defendant's motion to dismiss the Indictment. [Record No. 70] Girod has filed a Notice of Appeal regarding the Court's June 24, 2016 Memorandum Opinion and Order, and that attempted appeal is pending. [Record No. 71] As a result, the trial of this matter has been continued generally pending resolution of the interlocutory appeal and the United States' three motions, two of which are addressed here. [See Record No. 73.] First, the Government seeks to exclude Girod's proposed expert witness testimony as irrelevant and/or unreliable under Rules 402 and 702 of the Federal Rules of Evidence. [Record No. 68] Second, the United States asserts that Girod should not be able to present evidence regarding the sale of his products through a "Private Membership Association" because such a defense is not viable. [Record No. 67] The Court agrees with the United States and will grant its in limine requests.
The United States requests an in limine determination that Girod's proposed expert witnesses cannot offer their opinion testimony at trial. [Record No. 68, p. 1] In his "Expert Witness Notification," the defendant indicates his intent to present the testimony of 45 customers of his business who have used the salves at issue and can attest to their efficacy. [Record No. 53] The Government argues that the testimony is irrelevant under Rule 402 of the Federal Rules of Evidence and that it constitutes improper opinion evidence under Rule 702 and the holding in Daubert v. Merrell-Dow Pharmaceuticals, Inc., 509 U.S. 579, 591-92 (1993).
Irrelevant evidence is not admissible. Fed. R. Evid. 402. "Evidence is relevant if: (a) it has any tendency to make a fact more or less probable than it would be without the evidence;and (b) the fact is of consequence in determining the action. Fed. R. Evid. 401. Here, the efficacy of Girod's salves is not at issue. It is clearly irrelevant to the charges in the Indictment relating to obstruction of justice. [Record No. 1, ¶¶ 17-18, 23-24, 43-44] Nor is the efficacy of the salves relevant to the counts concerning violations of the Federal Food, Drug, and Cosmetic Act ("FDCA"). For instance, Count 3 charges Girod will failing to register with the FDA in accordance with 21 U.S.C. § 360. [Id., ¶ 26] Whether Girod's salves act as healing agents has nothing to do with whether Girod was properly registered with the FDA.
The remaining counts all address the inadequate labeling of Girod's products. See 21 U.S.C. §§ 331(a) and 333(a)(2). [Id., ¶¶ 27-42] Regardless of the benefits of the salves, the labeling could still be inadequate based on any potential dangers, or any failure to warn the customers about limitations and proper use of the products. Because the efficacy of the salves does not make it more or less probable that Girod violated the registration and labeling requirements of the FDCA, evidence concerning that issue must be excluded as irrelevant under Rule 402.
Next, Rule 702 provides that:
Fed. R. Evid. 702. The Rule reflects the Supreme Court's holding in Daubert, 509 U.S. at 592. See Fed. R. Evid. 702 Advisory Committee's Note (2000 Amendment). As the United States Court of Appeals for the Sixth Circuit explained in In re Scrap Metal AntitrustLitigation, a proposed expert's opinion testimony is admissible, at the district court's discretion, if three requirements are met: (1) the witness must be qualified by "knowledge, skill, experience, training, or education;" (2) the testimony must be relevant; and (3) the testimony must be reliable. 527 F.3d 517, 529 (6th Cir. 2008) (citing Fed. R. Evid. 702).
The United States argues that Girod's proposed opinion testimony fails to meet any of the three requirements outlined in In re Scrap Metal Antitrust Litigation. [Record No. 68, p. 3] First, Girod has not provided information regarding the witnesses' qualifications. Although they purport to have used the salves at issue, the defendant must establish that the proposed witnesses' backgrounds include "specialized" knowledge that is "beyond the scope of the ordinary juror." See Zuzula v. ABB Power T & D Co., 267 F. Supp. 2d 703, 713 (E.D. Mich. 2003). In Mahaney ex rel. Estate of Kyle v. Novartis Pharmaceuticals Corp., the district court excluded a lay witness' statement that a drug caused her bones to harden. 835 F. Supp. 2d 299, 304 (W.D. Ky. 2011). The court reasoned that the statement constituted inadmissible opinion evidence under Rule 701. Id. Girod's proposed witnesses resemble the witness in Mahaney. In reality, they are lay witnesses attempting to provide expert testimony that is improper under Rule 701.
Although "the accrual of specialized knowledge through experience is sufficient to create expertise," that experience must be extensive. United States v. Lawson, Criminal Action No. 3:08-21-DCR, 2009 WL 1208014, *4 (E.D. Ky. May 1, 2009) (); Fee v. Brass Eagle, Inc., No. 3:00CV7786, 2002 WL 1465762, *6 (N.D. Ohio Jun. 3, 2002) (). Here, on the other hand, Girod's proposed witnesses have not shown that they have extensive experience withsalves, the pharmaceutical industry, or FDCA regulations.1 In other words, Girod has failed to demonstrate that his proposed experts are qualified by specialized knowledge, skill, experience, training, or education as required by Rule 702. See Zuzula, 267 F. Supp. 2d at 713.
In addition, as explained above, the proposed testimony is irrelevant because it will not assist the jury in resolving a fact in issue. See Fed. R. Evid. 702(a). Although Girod's salves might cure some ills and operate safely under certain conditions, such benefits do not change the fact that he allegedly failed to comply with FDCA labeling and registration requirements. Moreover, the proposed statements are unreliable because they are not based on sufficient facts or data and are not the product of reliable principles and methods. See Fed. R. Evid. 702(b), (c). Instead, they are based entirely on limited personal experience. See, e.g., Avendt v. Covidien, Inc., ___ F.R.D. ___, 2016 WL 1566890, *14 (E.D. Mich. Apr. 19, 2016) () (quoting Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 152 (1999)). Because Girod's proposed opinion testimony is both irrelevant and unreliable, it will be excluded under Rule 702.
The United States also seeks to exclude at trial evidence regarding Girod's anticipated defense based on the sale of his products through a "Private Membership Association" ("PMA"). [Record No. 67, p. 1] By letters dated February 13 and 21, 2014, and September 8, 2015, Girod advised the FDA, Assistant District Attorney Curt Bohling, Assistant United States Attorney Andrew Boone, and Federal Investigator Steven Lamp that state and federal agencies have no jurisdiction to investigate or prosecute his activities conducted under the umbrella of a PMA. [Record Nos. 67-1; 67-2; 67-3] The defendant based his arguments on the free speech guarantees of the First and Fourteenth Amendments to the United States Constitution, as expressed in Nat'l Ass'n for Advancement of Colored People v. Button, 371 U.S. 415 (1963).
Although there is scant case law on this issue, the courts that have addressed it have determined that PMAs are subject to the requirements of the FDCA. See Lytle v. United States Dep't of Health & Human Servs., 612 F. App'x 861, 861-62 (8th Cir. 2015) (); United States v. Cole, 84 F. Supp. 3d 1159, 1170 (D. Or. 2015) (...
To continue reading
Request your trial